← Back to Clinical Trials
Recruiting NCT07439744

NCT07439744 NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07439744
Status Recruiting
Phase
Sponsor National Science and Technology Council, Taiwan
Condition Obese Adults
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2025-03-01
Primary Completion 2027-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 54 Years
Study Type INTERVENTIONAL
All Conditions
Interventions
Eicosapentaenoic acid (omega-3 fatty acid)Placebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2025-03-01 with a primary completion date of 2027-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g/day) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index \< 8%) (81), from the Taiwanese cohort. Associations with PLA2/COX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.

Eligibility Criteria

Inclusion Criteria: * Major depressive disorder. * Antidepressant drug-free. Exclusion Criteria: * Schizophrenia * Mania * Anxiety disorders (except for social phobia and generalized anxiety that are often comorbid with MDD) * Obsessive-compulsive disorder * Post-traumatic stress disorder * Alcohol or drug abuse/dependence (except for nicotine) * Active suicidal ideation * Serious medical/neurological conditions, especially requiring corticosteroid/non-steroidal anti-inflammatory or immunosuppressive therapies or chronic thyroid hormone replacement

Frequently Asked Questions

Who can join the NCT07439744 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 54 Years, studying Obese Adults. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07439744 currently recruiting?

Yes, NCT07439744 is actively recruiting participants. Visit ClinicalTrials.gov or contact National Science and Technology Council, Taiwan to inquire about joining.

Where is the NCT07439744 trial being conducted?

This trial is being conducted at Taichung, Taiwan.

Who is sponsoring the NCT07439744 clinical trial?

NCT07439744 is sponsored by National Science and Technology Council, Taiwan. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology